Animal Stem Cell Therapy Market: Overview, Opportunities, Analysis of Features, Benefits, Manufacturing Cost and Forecast To 2025 – Cole of Duty

The Global Animal Stem Cell Therapy Market report provides information by Key Players, Geography, End users, Applications, Competitor analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast.

Initially, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Animal Stem Cell Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Complete Report on Animal Stem Cell Therapy market spread across 144 pages and Top companies. Get SAMPLE at https://www.insidemarketreports.com/sample-request/10/334201/Animal-Stem-Cell-Therapy

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Global Animal Stem Cell Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

The Top players are MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics,.

The Report covers following things

The report introduces Animal Stem Cell Therapy basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Animal Stem Cell Therapy market for the coming few years have also been included in the report.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on global major leading Animal Stem Cell Therapy Market players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

The Animal Stem Cell Therapy industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

Purchase a copy of this report at https://www.insidemarketreports.com/buy-now/10/334201/Animal-Stem-Cell-Therapy/single

Purchase this Report now by availing up to 40% Discount and free consultation.Offer is valid for May 2020 only.

Table of Contents

1 Animal Stem Cell Therapy Market Overview

2 Global Animal Stem Cell Therapy Market Competition by Manufacturers

3 Global Animal Stem Cell Therapy Capacity, Production, Revenue (Value) by Region)

4 Global Animal Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region

5 Global Animal Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

6 Global Animal Stem Cell Therapy Market Analysis by Application

7 Global Animal Stem Cell Therapy Manufacturers Profiles/Analysis

8 Animal Stem Cell Therapy Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Animal Stem Cell Therapy Market Forecast

13 Research Findings and Conclusion

14 Appendix

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

Go here to read the rest:
Animal Stem Cell Therapy Market: Overview, Opportunities, Analysis of Features, Benefits, Manufacturing Cost and Forecast To 2025 - Cole of Duty

Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 – TheStreet

Courtesy of Alexander (Sasha) Poltorak, Tufts University

The killer is not the virus but the immune response.

The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable. In some it is strong enough to kill. In others it is relatively mild.

My research relates to innate immunity. Innate immunity is a persons inborn defense against pathogens that instruct the bodys adaptive immune system to produce antibodies against viruses. Those antibody responses can be later used for developing vaccination approaches. Working in the lab of Nobel laureate Bruce Beutler, I co-authored the paper that explained how the cells that make up the bodys innate immune system recognize pathogens, and how overreacting to them in general could be detrimental to the host. This is especially true in the COVID-19 patients who are overreacting to the virus.

I study inflammatory response and cell death, which are two principal components of the innate response. White blood cells called macrophages use a set of sensors to recognize the pathogen and produce proteins called cytokines, which trigger inflammation and recruit other cells of the innate immune system for help. In addition, macrophages instruct the adaptive immune system to learn about the pathogen and ultimately produce antibodies.

To survive within the host, successful pathogens silence the inflammatory response. They do this by blocking the ability of macrophages to release cytokines and alert the rest of the immune system. To counteract the viruss silencing, infected cells commit suicide, or cell death. Although detrimental at the cellular level, cell death is beneficial at the level of the organism because it stops proliferation of the pathogen.

For example, the pathogen that caused the bubonic plague, which killed half of the human population in Europe between 1347 and 1351, was able to disable, or silence, peoples white blood cells and proliferate in them, ultimately causing the death of the individual. However, in rodents the infection played out differently. Just the infected macrophages of rodents died, thus limiting proliferation of the pathogen in the rodents bodies which enabled them to survive.

The silent response to plague is strikingly different from the violent response to SARS-CoV-2, the virus that causes COVID-19. This suggests that keeping the right balance of innate response is crucial for the survival of COVID-19 patients.

Heres how an overreaction from the immune system can endanger a person fighting off an infection.

Some of the proteins that trigger inflammation, named chemokines, alert other immune cells like neutrophils, which are professional microbe eaters to convene at the site of infections where they can arrive first and digest the pathogen.

Others cytokines such as interleukin 1b, interleukin 6 and tumor necrosis factor guide neutrophils from the blood vessels to the infected tissue. These cytokines can increase heartbeat, elevate body temperature, trigger blood clots that trap the pathogen and stimulate the neurons in the brain to modulate body temperature, fever, weight loss and other physiological responses that have evolved to kill the virus.

When the production of these same cytokines is uncontrolled, immunologists describe the situation as a cytokine storm. During a cytokine storm, the blood vessels widen further (vasolidation), leading to low blood pressure and widespread blood vessel injury. The storm triggers a flood of white blood cells to enter the lungs, which in turn summon more immune cells that target and kill virus-infected cells. The result of this battle is a stew of fluid and dead cells, and subsequent organ failure.

The cytokine storm is a centerpiece of the COVID-19 pathology with devastating consequences for the host.

When the cells fail to terminate the inflammatory response, production of the cytokines make macrophages hyperactive. The hyperactivated macrophages destroy the stem cells in the bone marrow, which leads to anemia. Heightened interleukin 1b results in fever and organ failure. The excessive tumor necrosis factor causes massive death of the cells lining the blood vessels, which become clotted. At some point, the storm becomes unstoppable and irreversible.

One strategy behind the treatments for COVID is, in part, based in part on breaking the vicious cycle of the cytokine storm. This can be done by using antibodies to block the primary mediators of the storm, like IL6, or its receptor, which is present on all cells of the body.

Inhibition of tumor necrosis factor can be achieved with FDA-approved antibody drugs like Remicade or Humira or with a soluble receptor such as Enbrel (originally developed by Bruce Beutler) which binds to tumor necrosis factor and prevents it from triggering inflammation. The global market for tumor necrosis factor inhibitors is US$22 billion.

Drugs that block various cytokines are now in clinical trials to test whether they are effective for stopping the deadly spiral in COVID-19.

[Get facts about coronavirus and the latest research. Sign up for The Conversations newsletter.]

Alexander (Sasha) Poltorak, Professor of Immunology, Tufts University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Link:
Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - TheStreet

Looking toward the Future of Cell & Gene Therapies – Genetic Engineering & Biotechnology News

Broadcast Date: June 18, 2020Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Cell and Gene therapies continue to evolve in their use for treating human diseases. Cell-based therapies are emerging as a promising strategy for cancer, while AAV vectors have taken center stage as a gene delivery vehicle for potential gene therapy for several human diseases.

In this GEN webinar, our expert speakers, who are leading investigators in the field ofcell and gene therapy, will discuss emerging gene-edited and engineered cell therapies for cancer, as well as the next generation of AAV vectors for human gene therapy. Additionally, our speakers will cover some of the following key points:

Advancements in cell surface receptor-targeted adult stem cells, cancer cells, and T cells expressing novel bi-functional immunomodulatory proteins Demonstrate the strength of using innovative gene therapy approaches clinically Provide data and rationale for assessing combined cell- and gene-based approaches in preclinical studies

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Produced with support from:

See the original post here:
Looking toward the Future of Cell & Gene Therapies - Genetic Engineering & Biotechnology News

NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients – Yahoo…

NantKwest, Inc. (NASDAQ: NK) today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC, an allogeneic mesenchymal stem cell (MSC) product derived from human bone marrow. NantKwest has entered into an agreement with the National Marrow Donor Program (Be the Match) to provide donor material and has developed automated proprietary methods to expand and generate multiple dose forms utilizing a modular, closed system (GMP-in-a-box) from NantKwest affiliate ImmunityBio, Inc., to expand BM-Allo.MSCs, enabling the scalable manufacture and immediate distribution of cryopreserved BM-Allo.MSC product.

"There is an urgent need to develop broadly accessible treatment options for the devastating outcomes seen in the thousands of COVID-19 patients who are facing severe disease with ARDS and cytopathic storm," said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of NantKwest and ImmunityBio. "While MSC-derived treatments have shown promise in treating patients with ARDS, including those with COVID-19, the ability to scale production to support the overwhelming patient need has been a challenge. Our proprietary GMP-in-a-Box enables the rapid and scalable manufacture of our fully human BM-Allo.MSC product, overcoming this previous limitation to advance a promising new treatment to those patients who are most in need. Due to our proprietary methods, we are well positioned to rapidly advance BM-Allo.MSC during the current wave of COVID-19, with an anticipated trial initiation in Q2."

BM-Allo.MSC is a bone marrow-derived allogenic MSC product being developed to attenuate the inflammatory processes that drive ARDS in severe COVID-19 patients. MSCs are multipotent progenitor cells that give rise to cell types responsible for tissue repair and may restore effective immune function and contribute to viral clearance. Prior work with allogeneic MSC products in patients with ARDS has shown that such treatment is safe and may reduce key markers of inflammatory processes.

Trial Design

The Phase 1b, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BM-Allo.MSC versus current supporting care in treating patients with severe disease and requiring ventilator support (IND 019735). The therapeutic will be administered to a total of 45 patients receiving care in the critical care or ICU setting. The primary objectives of the study include overall safety and reduction in time on ventilator. The secondary objective will focus on the efficacy of BM-Allo.MSC in reducing the number of days patients require oxygen, duration of hospitalization, and mortality.

About NantKwest

NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally-induced infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized activated NK cellsas well as their activity against a broad range of cancershas been tested in Phase I clinical trials in Canada and Europe, as well as in multiple Phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwests goal is to transform medicine by delivering off-the-shelf living drugs-in-a-bag and bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit http://www.nantkwest.com

haNK is a registered trademark of NantKwest, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that NantKwest will be successful in improving the treatment of cancer and/or Covid-19. Risks and uncertainties related to this endeavor include, but are not limited to, obtaining FDA approval of NantKwests NK cells, as well as other therapeutics, as part of the NANT Cancer Vaccine platform as a cancer treatment and/or Covid-19 treatment.

Story continues

Forward-looking statements are based on managements current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.

These and other risks regarding NantKwests business are described in detail in its Securities and Exchange Commission filings, including in NantKwests Quarterly Report on Form 10-Q for the Quarter ended March 31, 2020. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005217/en/

Contacts

Jen HodsonJen@nant.com 562-397-3639

Excerpt from:
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients - Yahoo...

Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and…

NEW HAVEN, Conn., May 21, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, and Celularity, Inc., a leading developer of allogeneic, or off-the-shelf, natural killer (NK) cell therapies, today announced a preclinical research collaboration to rapidly advance synergistic combinations of each companys technology platform as potential treatments for COVID-19 and multiple myeloma.

The collaboration comes at an opportune time for both companies. Earlier this year, Kleo received IND authorization from the U.S. Food and Drug Administration (FDA) to test its CD38-targeting antibody recruiting molecule (ARMTM) in combination with autologous NK cells in a clinical study. In early April, Celularity received FDA authorization to evaluate one of its allogeneic NK cell products, CYNK-001, in COVID-19 infected adults. CYNK-001 is the only cryopreserved allogeneic, off-the-shelf Natural Killer (NK) cell therapy being developed from placental hematopoietic stem cells. It also is being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and glioblastoma multiforme (GBM).

We look forward to working with Celularity to advance the ARMTM technology platform across multiple drug programs, said Doug Manion, MD, CEO of Kleo Pharmaceuticals. Celularitys cryopreserved allogeneic NK cells easily combine with the ARMTM platform, which is expected to facilitate NK cell targeting toward cancerous tumors or sites of viral infection. Celularitys CEO Robert Hariri, MD, PhD added, We quickly realized the advantages of Kleos synthetic bifunctional technology, and the synergistic potential between ARMTM molecules and our allogeneic NK cells. The speed and modularity of the Kleo platform allow for the development of ARMTM-allogeneic NK cell combination therapies across a wide variety of indications.

When used in combination with NK cells, ARMTM molecules behave similarly to chimeric antigen receptors, though their synthetic nature eliminates the need for genetic engineering. ARMTM molecules associate with NK cells via IgG antibodies bound to a first moiety, while also containing an interchangeable and customizable second moiety. Selection of the second moiety can be used to confer affinity of an ARMTM-NK cell complex against a biological target, such as the spike protein of COVID-19 particles or CD38 expressed on the surface of multiple myeloma hematologic tumors, ultimately facilitating NK-cell mediated destruction of target cells. This modular design allows ARMTM molecules to be broadly applicable across a range of drug programs.

About Kleo Pharmaceuticals, Inc.

Kleo Pharmaceuticals is a unique biotechnology company developing next-generation, bispecific compounds designed to emulate or enhance the activity of biologics based on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Kleos compounds are designed to direct the immune system to destroy cancerous or virally infected cells and are currently in development for the treatment of various diseases, including multiple myeloma and COVID-19. Compared to biologics, Kleos compounds are smaller and more versatile, leading to potentially improved safety and efficacy. They are also much faster and more efficient to design and produce, particularly against novel targets. Kleo develops drug candidates based on its proprietary technology platforms, all of which are modular in design and enable rapid generation of novel immunotherapies that can be optimized against specified biological targets and combined with existing cell- or antibody-based therapies. These include Antibody Recruiting Molecules (ARMs) and Monoclonal Antibody Therapy Enhancers (MATEs). Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc. (Nikkei:PPTDF) are investors in Kleo Pharmaceuticals. For more information visit http://kleopharmaceuticals.com.

About Celularity

Celularity, headquartered in Warren, N.J., is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases. To learn more, please visit http://www.celularity.com.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will, "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT INFORMATION

LifeSci Advisors (Investors)

Irina Koffler

646-970-4681

ikoffler@lifesciadvisors.com

Kleo Pharmaceuticals (Media)

Brian Dowd

(203) 643-9172

bdowd@kleopharmaceuticals.com

Celularity Inc. Media Contact:

Dani Frank

Factory PR

celularity@factorypr.com

Read the original post:
Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and...

Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 – The Conversation US

The killer is not the virus but the immune response.

The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable. In some it is strong enough to kill. In others it is relatively mild.

My research relates to innate immunity. Innate immunity is a persons inborn defense against pathogens that instruct the bodys adaptive immune system to produce antibodies against viruses. Those antibody responses can be later used for developing vaccination approaches. Working in the lab of Nobel laureate Bruce Beutler, I co-authored the paper that explained how the cells that make up the bodys innate immune system recognize pathogens, and how overreacting to them in general could be detrimental to the host. This is especially true in the COVID-19 patients who are overreacting to the virus.

I study inflammatory response and cell death, which are two principal components of the innate response. White blood cells called macrophages use a set of sensors to recognize the pathogen and produce proteins called cytokines, which trigger inflammation and recruit other cells of the innate immune system for help. In addition, macrophages instruct the adaptive immune system to learn about the pathogen and ultimately produce antibodies.

To survive within the host, successful pathogens silence the inflammatory response. They do this by blocking the ability of macrophages to release cytokines and alert the rest of the immune system. To counteract the viruss silencing, infected cells commit suicide, or cell death. Although detrimental at the cellular level, cell death is beneficial at the level of the organism because it stops proliferation of the pathogen.

For example, the pathogen that caused the bubonic plague, which killed half of the human population in Europe between 1347 and 1351, was able to disable, or silence, peoples white blood cells and proliferate in them, ultimately causing the death of the individual. However, in rodents the infection played out differently. Just the infected macrophages of rodents died, thus limiting proliferation of the pathogen in the rodents bodies which enabled them to survive.

The silent response to plague is strikingly different from the violent response to SARS-CoV-2, the virus that causes COVID-19. This suggests that keeping the right balance of innate response is crucial for the survival of COVID-19 patients.

Heres how an overreaction from the immune system can endanger a person fighting off an infection.

Some of the proteins that trigger inflammation, named chemokines, alert other immune cells like neutrophils, which are professional microbe eaters to convene at the site of infections where they can arrive first and digest the pathogen.

Others cytokines such as interleukin 1b, interleukin 6 and tumor necrosis factor guide neutrophils from the blood vessels to the infected tissue. These cytokines can increase heartbeat, elevate body temperature, trigger blood clots that trap the pathogen and stimulate the neurons in the brain to modulate body temperature, fever, weight loss and other physiological responses that have evolved to kill the virus.

When the production of these same cytokines is uncontrolled, immunologists describe the situation as a cytokine storm. During a cytokine storm, the blood vessels widen further (vasolidation), leading to low blood pressure and widespread blood vessel injury. The storm triggers a flood of white blood cells to enter the lungs, which in turn summon more immune cells that target and kill virus-infected cells. The result of this battle is a stew of fluid and dead cells, and subsequent organ failure.

The cytokine storm is a centerpiece of the COVID-19 pathology with devastating consequences for the host.

When the cells fail to terminate the inflammatory response, production of the cytokines make macrophages hyperactive. The hyperactivated macrophages destroy the stem cells in the bone marrow, which leads to anemia. Heightened interleukin 1b results in fever and organ failure. The excessive tumor necrosis factor causes massive death of the cells lining the blood vessels, which become clotted. At some point, the storm becomes unstoppable and irreversible.

One strategy behind the treatments for COVID is, in part, based in part on breaking the vicious cycle of the cytokine storm. This can be done by using antibodies to block the primary mediators of the storm, like IL6, or its receptor, which is present on all cells of the body.

Inhibition of tumor necrosis factor can be achieved with FDA-approved antibody drugs like Remicade or Humira or with a soluble receptor such as Enbrel (originally developed by Bruce Beutler) which binds to tumor necrosis factor and prevents it from triggering inflammation. The global market for tumor necrosis factor inhibitors is US$22 billion.

Drugs that block various cytokines are now in clinical trials to test whether they are effective for stopping the deadly spiral in COVID-19.

[Get facts about coronavirus and the latest research. Sign up for The Conversations newsletter.]

More here:
Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - The Conversation US

Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio – Business…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the stem cell therapy market and it is poised to grow by USD 588.22 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. are some of the major market participants. The increase in awareness of stem cell therapy will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.

Stem Cell Therapy Market 2020-2024: Segmentation

Stem Cell Therapy Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43432

Stem Cell Therapy Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our stem cell therapy market report covers the following areas:

This study identifies limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.

Stem Cell Therapy Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the stem cell therapy market, including some of the vendors such as Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. Backed with competitive intelligence and benchmarking, our research reports on the stem cell therapy market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Stem Cell Therapy Market 2020-2024: Key Highlights

Table Of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Visit link:
Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio - Business...

NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients – Business…

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC, an allogeneic mesenchymal stem cell (MSC) product derived from human bone marrow. NantKwest has entered into an agreement with the National Marrow Donor Program (Be the Match) to provide donor material and has developed automated proprietary methods to expand and generate multiple dose forms utilizing a modular, closed system (GMP-in-a-box) from NantKwest affiliate ImmunityBio, Inc., to expand BM-Allo.MSCs, enabling the scalable manufacture and immediate distribution of cryopreserved BM-Allo.MSC product.

There is an urgent need to develop broadly accessible treatment options for the devastating outcomes seen in the thousands of COVID-19 patients who are facing severe disease with ARDS and cytopathic storm, said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of NantKwest and ImmunityBio. While MSC-derived treatments have shown promise in treating patients with ARDS, including those with COVID-19, the ability to scale production to support the overwhelming patient need has been a challenge. Our proprietary GMP-in-a-Box enables the rapid and scalable manufacture of our fully human BM-Allo.MSC product, overcoming this previous limitation to advance a promising new treatment to those patients who are most in need. Due to our proprietary methods, we are well positioned to rapidly advance BM-Allo.MSC during the current wave of COVID-19, with an anticipated trial initiation in Q2.

BM-Allo.MSC is a bone marrow-derived allogenic MSC product being developed to attenuate the inflammatory processes that drive ARDS in severe COVID-19 patients. MSCs are multipotent progenitor cells that give rise to cell types responsible for tissue repair and may restore effective immune function and contribute to viral clearance. Prior work with allogeneic MSC products in patients with ARDS has shown that such treatment is safe and may reduce key markers of inflammatory processes.

Trial Design

The Phase 1b, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BM-Allo.MSC versus current supporting care in treating patients with severe disease and requiring ventilator support (IND 019735). The therapeutic will be administered to a total of 45 patients receiving care in the critical care or ICU setting. The primary objectives of the study include overall safety and reduction in time on ventilator. The secondary objective will focus on the efficacy of BM-Allo.MSC in reducing the number of days patients require oxygen, duration of hospitalization, and mortality.

About NantKwest

NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally-induced infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized activated NK cellsas well as their activity against a broad range of cancershas been tested in Phase I clinical trials in Canada and Europe, as well as in multiple Phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwests goal is to transform medicine by delivering off-the-shelf living drugs-in-a-bag and bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit http://www.nantkwest.com

haNK is a registered trademark of NantKwest, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that NantKwest will be successful in improving the treatment of cancer and/or Covid-19. Risks and uncertainties related to this endeavor include, but are not limited to, obtaining FDA approval of NantKwests NK cells, as well as other therapeutics, as part of the NANT Cancer Vaccine platform as a cancer treatment and/or Covid-19 treatment.

Forward-looking statements are based on managements current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.

These and other risks regarding NantKwests business are described in detail in its Securities and Exchange Commission filings, including in NantKwests Quarterly Report on Form 10-Q for the Quarter ended March 31, 2020. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Read more here:
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients - Business...

Stem Cell Therapy Improved Quality of Life in Patients with Microvascular Dysfunction – Diagnostic and Interventional Cardiology

May 17, 2020 Trial results presented today revealed a promising therapy for patients experiencing angina due to coronary microvascular dysfunction (CMD). The results of the study were presented as feature clinical research during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference. CMD is heart disease that causes the small blood vessels feeding the heart muscle to not work as normal. CMD results in ischemia, angina and adverse outcomes in patients with non-obstructive coronary artery disease (NOCAD), with a high predilection for women. Patients experience significant impairment in their quality of life, and no specific therapy for CMD exists.

The authors concluded that CD34+ cell therapy appears to be a promising therapy for CMD patients with angina and NOCAD. A prospective, randomized clinical trial is forthcoming.

This was a proof of concept trial to evaluate the safety and efficacy of CD34+ stem cells administered via intracoronary infusion for CMD patients with abnormal coronary flow reserve of less than 2.5, said Timothy D. Henry, M.D., MSCAI, lead author of the study and SCAI vice president. Our results demonstrate a significant improvement in coronary flow reserve with a single intracoronary infusion of CD34+ cells as well as a significant improvement in angina and quality of life.

CD34+ cell therapy augments microvasculature in preclinical models and improves symptoms, exercise tolerance and mortality in refractory angina obstructive coronary artery disease patients. CD34+ stem cells are a naturally occurring endothelial progenitor cell shown in pre-clinical models to improve microvascular angiogenesis in ischemic tissues. Clinical studies in refractory angina, critical limb ischemia, and dilated cardiomyopathy have shown therapeutic benefit, including reduction in angina, improvement in exercise time, a reduction in amputation and mortality.

Researchers conducted a two-center NHLBI-sponsored (R44HL135889)1 trial of autologous CD34+ cell therapy (CLBS16-P01) (NCT03508609) in 20 NOCAD patients with persistent angina and invasive coronary flow reserve (CFR) 2.5. Measures included angina frequency, CCS Class, Seattle Angina Questionnaire (SAQ), modified Bruce exercise treadmill test (ETT), and labs. Subjects received GCSF 5 mcg/kg/day for 5 days before leukapheresis, followed by manufacturing to select the CD34+ cells.

Cells were administered via a single infusion to the LAD coronary artery. Six-month assessment included invasive CFR, angina frequency, CCS, SAQ and ETT.CFR significantly increased from 2.08+/-0.3 at baseline to 2.68+/-0.8 at 6 months after a single infusion of CD34+ cells (p=0.0045) and study investigators reported that there were no cell-related adverse events.

Find links to the rest of the SCAI late-breaking trials and other SCAI news

Originally posted here:
Stem Cell Therapy Improved Quality of Life in Patients with Microvascular Dysfunction - Diagnostic and Interventional Cardiology

Can stem cell therapy help – Greater Kashmir

Currently definitive treatment against civid is unavailable while patients are being offered palliative treatment to manage symptoms. Many known therapeutic agents like antivirals (Remdesivir or Hydroxychloroquine) or antiparasitic (Ivermectin) are being evaluated for their efficacy against the disease, although without any comprehensive success. Similarly, the exhaustive work is going on to develop the vaccine against the COVID-19 but that too requires lot more efforts and time. There is lot of buzz about the safety and efficacy of stem cell therapy in COVID-19 patients. Even some have claimed its efficacy far closer to the definitive treatment. The question is whether it really is the treatment of choice is being discussed here.

Stem cells are of various types including the embryonic cells (embryonic stem cells) and those harvested form the adult body tissues (like mesenchymal stem cells). Embryonic stem cells carry good differentiation potential as compared to the adult mesenchymal stem cells (MSCs). Due to the ethical and the teratogenic (tumour forming potential) issues MSCs are being favoured over embryonic stem cells (ESCs). MSCs additionally offer immuno-modulatory and / anti-inflammatory effects and can be harvested from numerous tissue sources including the foetal membranes. As MSCs are immune-compromised (weak potential to elicit immune response), there allogeneic (from other sources) utilization as ready-to-use source becomes possible. MSCs safety and efficacy in various non-infectious immune mediated diseases like Graft-vs-Host disease (GVHD) and Systemic Lupus Erythromatosis (SLE), among others has already been established. MSCs immune-modulation may be achieved either through the direct cell-to-cell contact or through their secretome being enhanced by the inflammatory mediators. Additionally, compared to the drugs that block inflammatory response (IL-6) like tocilizumab MSCs may prove superior by promoting healing of the damaged tissues through their tissue specific differentiation and recruitment of other pro-healing cells.

COVID-19 affects the elderly much more than the young ones and as much as 8 out of 10 patients above 65 years are hard hit. This is due to their weak immune response against the disease as compared to the young ones. In case of some young ones that gets badly affected, harmless genetic or environmental factors might make the immune response overdrive. The inflammatory cells secrete excessive quantity of cytokines without an ability to switch off and form a chain reaction leading to the cytokine storm. This unchecked inflammation and its mediators flood lungs and give rise to acute respiratory distress syndrome (ARDS). MSCs due to the characteristic immune-modulatory features may balance the immune response and prevent overdrive immune response in young ones while in case of elderly patients lack of the sufficient immune response may be compensated. It is worth mentioning here that MSCs directly may not affect the virus but due to their characteristic properties adverse reactions due to viral infection may be prevented.

MSCs are being categorized as Advanced Therapy Medicinal Products (ATMPs) by European Medicines Agency (EMA), meaning possible adverse reaction can arise with their use. Initial clinical trials conducted in China on COVID-19 patients have confirmed their safety and efficacy. Food and Drug Administration (FDA) as such has approved the compassionate use of the allogeneic MSCs. Stem cell therapy for COVID-19 is under clinical trials with little available data that confirms their safety and efficacy to treat the patients. These cells are being used in seriously ill patients due to unavailability of the specific treatment. MSCs clinical trials have been conducted in various parts of the world including the China, USA and Australia. Available reports of different allogeneic MSCs clinical trials have demonstrated improvement in seriously ill COVID-19 patients. Even COVID-19 patients with liver injury and cytokine storm too have been demonstrated to improve. At present MSCs approved compassionate (emergency) use is to prevent cytokine storm, however, the potential may go beyond and their applications can offer disease prevention as well.

MSCs as already discussed may not be free of risk. The recent evidences of disseminated intravascular coagulation (DIC) in COVID-19 demands further incites on MSCs applications as few experimental studies have reported intravascular coagulation with intravenous injection of MSCs. The under trial clinical studies vary from each other with respect to the patient inclusion and the doses of the cells given. The evaluation criteria need to be extensive, effective and uniform among the studies to develop evidence based medicine. It can be concluded that currently stem cell therapy for COVID-19 is under clinical trials and all the queries related to their safety, feasibility and efficacy need to be confirmed to arrive at any conclusion(s).

Dr Mudasir Bashir Gugjoo is Assistant Professor /Principal Investigator, Stem Cell Research Project FVSc & AH, SKUAST-Kashmir

Read the original post:
Can stem cell therapy help - Greater Kashmir